Advances in HIV 2020

Advances_in_HIV_theme_Banner

About the Program:

Target Audience
Program Objectives
Faculty
Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Disclaimer
Computer System Requirements

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Program Objectives:

Upon completion of the program, participants should be able to:

Utilize current and emerging data on HIV therapies and treatment paradigms to improve the treatment of HIV-positive patients
Address and reduce side effects from ARVs that can interfere with adherence to ARV regimens
Understand and apply in a clinical setting information about new paradigms and approaches to treating and managing HIV, including potential two-drug ARV combinations
Provide rapid initiation of ARV therapy following an HIV diagnosis
Apply new and emerging information on long-acting ARVs to their clinical practice
Discuss future directions in HIV treatment and HIV cure research

Release Date: June 12, 2020

Expiration Date: June 12, 2021

Estimated time to complete each Module: 15-45 minutes

Media: Web

Back to Top

Faculty:

Joseph Eron, MD
Professor of Medicine, School of Medicine Chief
Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Renslow Sherer, MD (Course Reviewer)
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and ViralEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

Back to Top

Credit Designation:

Module 1: COVID-19 and HIV Discussion
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2: Treatment-Naive -When and What to Start, Rapid Initiation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3: Treatment-Experienced - ARV Regimen Simplification
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 4: Treatment-Experienced - Two Drugs vs. Three, Unknown Resistance
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 5: Treatment-Experienced - Three Drugs vs. Four, Resistance and HCV Co-Infection
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 6: Weight Gain after Starting Antiretrovials
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 7: Adverse Event Management after Rapid Initiation of ART
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Joseph Eron, MD

•Consulting Fees: Gilead, ViiV, Merck

•Contracted Research: Gilead, ViiV, Janssen

Ian Frank, MD

•Consulting Fees: Gilead, GSK

•Contracted Research: Johnson & Johnson

Paul Sax, MD

•Consulting Fees: Gilead, GSK/ViiV, Merck, Janssen

•Contracted Research: Gilead, Merck, GSK/ViiV

•Editorial Positions: UpToDate, Medscape, NEJM Journal Watch, Open Forum Infectious Diseases

Renlsow Sherer, MD

•Nothing to Disclose

University of Chicago Center for Continuing Medical Education and ViralEd, Inc Declarations
The staff of the Center for Continuing Medical Education and Viral Ed Inc. have no financial relationships to disclose.

Back to Top

Disclaimer:

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright © 2020 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.

Back to Top

Computer System Requirements:

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.